Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

PDL BioPharma Company Profile (NASDAQ:PDLI)

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)
Ratings Breakdown: 2 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.75 (4.04% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/6/2014ZacksReiterated RatingNeutral -> Neutral$9.00ViewTweet This Rating  Share This Rating on StockTwits
1/3/2014ZacksReiterated RatingNeutral -> Neutral$9.00ViewTweet This Rating  Share This Rating on StockTwits
11/8/2013ZacksReiterated RatingNeutral -> Neutral$8.50ViewTweet This Rating  Share This Rating on StockTwits
10/18/2013ZacksReiterated RatingNeutral -> Neutral$8.50ViewTweet This Rating  Share This Rating on StockTwits
8/13/2013ZacksReiterated RatingNeutral -> Neutral$8.75ViewTweet This Rating  Share This Rating on StockTwits
5/16/2013ZacksReiterated RatingNeutral -> Neutral$8.75ViewTweet This Rating  Share This Rating on StockTwits
5/14/2013Piper JaffrayInitiated CoverageNeutral$8.50ViewTweet This Rating  Share This Rating on StockTwits
3/6/2013JPMorgan Chase & Co.Lower Price TargetNeutral$7.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
1/15/2013Credit SuisseDowngradeNeutral -> Underperform$6.50 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
1/3/2013Janney Montgomery ScottInitiated CoverageNeutral$7.00ViewTweet This Rating  Share This Rating on StockTwits
1/2/2013Janney Montgomery ScottInitiated CoverageNeutralViewTweet This Rating  Share This Rating on StockTwits
12/6/2012Credit SuisseInitiated CoverageNeutralViewTweet This Rating  Share This Rating on StockTwits
11/12/2012Credit SuisseInitiated CoverageNeutral$6.50ViewTweet This Rating  Share This Rating on StockTwits
8/24/2012ThinkEquityInitiated CoverageHoldViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/20/2012 forward)